| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1363737 | Bioorganic & Medicinal Chemistry Letters | 2009 | 5 Pages |
Abstract
We describe efforts to improve the pharmacokinetic profile of the aminopyridopyrazinone class of PDE5 inhibitors. These efforts led to the discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent and selective inhibitor of PDE5 with an excellent PK profile.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
![Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one](/preview/png/1363737.png "First Page Preview: Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one")
Authors
Robert O. Hughes, John K. Walker, D. Joseph Rogier, Steve E. Heasley, Rhadika M. Blevis-Bal, Alan G. Benson, E. Jon Jacobsen, Jerry W. Cubbage, Yvette M. Fobian, Dafydd R. Owen, John N. Freskos, John M. Molyneaux, David L. Brown, Brad A. Acker,